Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Operating Leases: 2019-2025

Historic Operating Leases for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $480,000.

  • Eton Pharmaceuticals' Operating Leases rose 280.95% to $480,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $480,000, marking a year-over-year increase of 280.95%. This contributed to the annual value of $107,000 for FY2024, which is 386.36% up from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' Operating Leases is $480,000, which was down 2.44% from $492,000 recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Operating Leases ranged from a high of $492,000 in Q2 2025 and a low of $15,000 during Q4 2021.
  • Its 3-year average for Operating Leases is $158,364, with a median of $87,000 in 2025.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Operating Leases slumped by 84.85% in 2021, and later spiked by 613.33% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' Operating Leases (Quarterly) stood at $15,000 in 2021, then surged by 613.33% to $107,000 in 2022, then slumped by 79.44% to $22,000 in 2023, then soared by 386.36% to $107,000 in 2024, then surged by 280.95% to $480,000 in 2025.
  • Its Operating Leases stands at $480,000 for Q3 2025, versus $492,000 for Q2 2025 and $87,000 for Q1 2025.